The Board of Directors of FIT Biotech Decides on Conversion of Shares – FIT Biotech

Reports and Releases

The Board of Directors of FIT Biotech Decides on Conversion of Shares

Company Release, September 8, 2015 at 15.00 EET

The Board of Directors of FIT Biotech Decides on Conversion of Shares

Today, the board of directors of FIT Biotech Oy (the 'Company') decided on the conversion of shares representing different series of shares in the Company in accordance with the conversion commitment submitted by the shareholder to the Company.

The board decided on the conversion of 3,000 D shares into K shares in accordance with section 5 of the Company's articles of association (1:1). After the conversion, the Company will have 27,599,817 K shares, 5,229 A shares and 65,235 D shares. The total number of shares in the Company, 27,670,281, is not affected by the conversion.

The Company's K shares are traded under the trading symbol FITBIO on the multilateral First North market maintained by the Helsinki Stock Exchange.

The date of entry in the Trade Register of the converted K shares and the first trading date of the converted K shares on First North will be announced separately.

FIT BIOTECH OY
Board of Directors

Additional information:
CEO Kalevi Reijonen, FIT Biotech Oy
Email: kalevi.reijonen@fitbiotech.com  
Phone: +358 40 843 5695

Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790

FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU ® (Gene Transport Unit) technology. Through GTU technology, FIT Biotech develops DNA vaccines in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development. FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at www.fitbiotech.com.

DISTRIBUTION:
NASDAQ OMX Helsinki
Major media
www.fitbiotech.com

Back to list